The schizophrenia market size is expected to grow during the forecast period (2025–2034). DelveInsight’s analysis projects growth in the schizophrenia market, driven by rising disease prevalence, the ...

Good day, and welcome to the Bristol Myers Squibb First Quarter 2025 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there ...

The newly approved schizophrenia drug, Cobenfy, generated sales of $27 million ... It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it.

Bristol Myers Squibb stock reversed higher Thursday after the drugmaker beat first-quarter expectations and raised its ...

The approval of Cobenfy for schizophrenia broadens BMY’s portfolio and validates the acquisition of Karuna Therapeutics. While the newer drugs boost ... 9,000th the size of NVIDIA which ...

Further, the company’s large size confers significant competitive ... The recent approval of Karuna’s schizophrenia drug Cobenfy stands to generate multi-billion-dollar peak sales in neurology ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ...

Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in $27 million in net sales in the first three months of the year — beating Wall Street sales expectations and analyst predictions.

The Phase 3 test evaluated the drug, Cobenfy, as an adjunct to atypical antipsychotics in adults whose schizophrenia symptoms were inadequately controlled by these standard-of-care drugs.